[Asia Economy Reporter Yoo Hyun-seok] Leaders Technology Investment announced on the 10th that the payment for the sale of convertible bonds (CB) worth 15.4 billion KRW has been completed.
Leaders Technology Investment plans to use the secured funds to strengthen capabilities through investment in future strategic businesses and business diversification. The company intends to focus on investments in bio-businesses such as bio funds to maximize investment returns.
Leaders Technology Investment has been actively investing in the bio-business since last year. Thanks to the investment performance in related bio companies such as COVID-19 diagnostic kits and therapeutics, the company recorded an earnings surprise last year. For the fiscal year ending in March, Leaders Technology Investment achieved cumulative operating revenue of 35.7 billion KRW and net profit of 9.4 billion KRW in the fourth quarter, significantly expanding both scale and profitability.
This year, the company plans to continuously discover ventures and new technology companies with potential and continue aggressive investments. To this end, it has also formed a professional advisory council. Recently, Leaders Technology Investment appointed Hong Kyung-pyo, president of the ‘Yunsamo’ Central Association, Kim Oh-jin, former Secretary General 1 of the Presidential Office, and Kang Choong-kyung, CEO of Pepsgen, as management advisors.
A company official stated, “The cash inflow of 15.4 billion KRW through the resale of CBs held by the company has enabled us to strengthen market competitiveness through expanded investments,” adding, “We plan to continue aggressive investments based on the funds from this CB sale and existing cash assets.” He further added, “We plan to diversify our investment portfolio including bio fund investments and will maximize corporate value through stable investment performance this year as well.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
